Shanghai Runda Med Tech Co Net Assets
Shanghai Runda Med Tech Co net assets. Based on the latest financial reports, Shanghai Runda Med Tech Co (603108) has net assets worth CN¥5.38 Billion CNY (≈ $787.48 Million USD) as of June 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥13.79 Billion ≈ $2.02 Billion USD) and total liabilities (CN¥8.41 Billion ≈ $1.23 Billion USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore Shanghai Runda Med Tech Co annual equity growth to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥5.38 Billion |
| % of Total Assets | 39.03% |
| Annual Growth Rate | 27.97% |
| 5-Year Change | 37.35% |
| 10-Year Change | 503.54% |
| Growth Volatility | 43.4 |
Net Assets of Shanghai Runda Med Tech Co (2014–2024)
Net assets of Shanghai Runda Med Tech Co from 2014 to 2024. This chart illustrates how Shanghai Runda Med Tech Co's net assets have evolved over time, based on quarterly financial data. See Shanghai Runda Med Tech Co (603108) balance sheet quality index to measure how much of total assets are equity-financed.
Annual Net Assets for Shanghai Runda Med Tech Co (2014–2024)
The table below shows the annual net assets of Shanghai Runda Med Tech Co from 2014 to 2024. For live market cap and overall valuation, see how much is Shanghai Runda Med Tech Co worth.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥5.60 Billion ≈ $820.06 Million |
+2.88% |
| 2023-12-31 | CN¥5.45 Billion ≈ $797.10 Million |
+8.73% |
| 2022-12-31 | CN¥5.01 Billion ≈ $733.10 Million |
+14.07% |
| 2021-12-31 | CN¥4.39 Billion ≈ $642.69 Million |
+7.64% |
| 2020-12-31 | CN¥4.08 Billion ≈ $597.07 Million |
+16.03% |
| 2019-12-31 | CN¥3.52 Billion ≈ $514.56 Million |
+12.31% |
| 2018-12-31 | CN¥3.13 Billion ≈ $458.14 Million |
+13.91% |
| 2017-12-31 | CN¥2.75 Billion ≈ $402.20 Million |
+23.69% |
| 2016-12-31 | CN¥2.22 Billion ≈ $325.17 Million |
+139.31% |
| 2015-12-31 | CN¥928.55 Million ≈ $135.88 Million |
+95.23% |
| 2014-12-31 | CN¥475.63 Million ≈ $69.60 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Shanghai Runda Med Tech Co's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 669.3% over the analyzed period, indicating profitable operations and earnings retention.
Shanghai Runda Med Tech Co Net Assets Breakdown (December 2024)
Shanghai Runda Med Tech Co net assets breakdown by equity component as of December 2024.
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥2.34 Billion | 53.64% |
| Other Components | CN¥2.02 Billion | 46.36% |
| Total Equity | CN¥4.35 Billion | 100.00% |
Shanghai Runda Med Tech Co Competitors by Market Cap
The table below lists competitors of Shanghai Runda Med Tech Co ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
CureVac NV
F:5CV
|
$885.32 Million |
|
Flotek Industries Inc
NYSE:FTK
|
$885.59 Million |
|
Neurones
PA:NRO
|
$885.97 Million |
|
Montnets Cloud Technology Group Co Ltd
SHE:002123
|
$886.30 Million |
|
Daily Journal Corp
NASDAQ:DJCO
|
$884.95 Million |
|
LIFETECH SCI.DL-00000125
F:81X
|
$884.93 Million |
|
CWB Automotive Electronics Co Ltd
SHG:605005
|
$884.88 Million |
|
Cementos Pacasmayo SAA ADR
NYSE:CPAC
|
$884.47 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Shanghai Runda Med Tech Co's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 4,280,104,992 to 4,354,582,007, a change of 74,477,015 (1.7%).
- Net income of 55,280,608 contributed positively to equity growth.
- Dividend payments of 337,343,818 reduced retained earnings.
- Other factors increased equity by 356,540,225.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥55.28 Million | +1.27% |
| Dividends Paid | CN¥337.34 Million | -7.75% |
| Other Changes | CN¥356.54 Million | +8.19% |
| Total Change | CN¥- | 1.74% |
Book Value vs Market Value Analysis
This analysis compares Shanghai Runda Med Tech Co's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.39x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 2.54x to 1.39x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | CN¥3.95 | CN¥10.02 | x |
| 2018-12-31 | CN¥4.32 | CN¥10.02 | x |
| 2019-12-31 | CN¥4.76 | CN¥10.02 | x |
| 2020-12-31 | CN¥5.53 | CN¥10.02 | x |
| 2021-12-31 | CN¥5.97 | CN¥10.02 | x |
| 2022-12-31 | CN¥6.71 | CN¥10.02 | x |
| 2023-12-31 | CN¥7.17 | CN¥10.02 | x |
| 2024-12-31 | CN¥7.21 | CN¥10.02 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Shanghai Runda Med Tech Co utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 1.27%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.67%
- • Asset Turnover: 0.58x
- • Equity Multiplier: 3.29x
- Recent ROE (1.27%) is below the historical average (9.29%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2014 | 15.81% | 5.61% | 1.24x | 2.28x | CN¥27.62 Million |
| 2015 | 9.93% | 5.63% | 0.96x | 1.83x | CN¥-641.67K |
| 2016 | 5.50% | 5.38% | 0.53x | 1.94x | CN¥-95.30 Million |
| 2017 | 9.58% | 5.08% | 0.61x | 3.12x | CN¥-9.52 Million |
| 2018 | 10.45% | 4.39% | 0.79x | 3.01x | CN¥11.40 Million |
| 2019 | 11.22% | 4.39% | 0.78x | 3.27x | CN¥33.67 Million |
| 2020 | 10.30% | 4.67% | 0.69x | 3.18x | CN¥9.64 Million |
| 2021 | 10.98% | 4.29% | 0.74x | 3.47x | CN¥33.96 Million |
| 2022 | 10.74% | 3.98% | 0.72x | 3.73x | CN¥28.91 Million |
| 2023 | 6.39% | 2.99% | 0.64x | 3.34x | CN¥-154.71 Million |
| 2024 | 1.27% | 0.67% | 0.58x | 3.29x | CN¥-380.18 Million |
Industry Comparison
This section compares Shanghai Runda Med Tech Co's net assets metrics with peer companies in the Diagnostics & Research industry.
Industry Context
- Industry: Diagnostics & Research
- Average net assets among peers: $3,756,384,293
- Average return on equity (ROE) among peers: 18.06%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Shanghai Runda Med Tech Co (603108) | CN¥5.38 Billion | 15.81% | 1.56x | $885.13 Million |
| Berry Genomics Co Ltd (000710) | $122.50 Million | 0.41% | 1.90x | $493.00 Million |
| Zhejiang DiAn Diagnostics Co (300244) | $9.50 Billion | 15.09% | 1.22x | $1.96 Billion |
| Hangzhou Tigermed Consulting (300347) | $17.86 Billion | 9.80% | 0.09x | $5.57 Billion |
| Beijing Strong Biotechnologies Inc (300406) | $1.39 Billion | 19.57% | 0.06x | $1.10 Billion |
| Ningbo MedicalSystem Biotechnology Co Ltd (300439) | $1.69 Billion | 17.75% | 0.93x | $542.70 Million |
| Maccura Biotechnology Co Ltd (300463) | $2.86 Billion | 15.53% | 0.59x | $801.64 Million |
| Guangdong Hybribio Biotech Co Ltd (300639) | $191.38 Million | 15.24% | 0.42x | $543.02 Million |
| BGI Genomics Co Ltd (300676) | $3.17 Billion | 8.27% | 0.23x | $2.35 Billion |
| Amoy Diagnostics Co Ltd (300685) | $649.20 Million | 14.49% | 0.07x | $1.09 Billion |
| Shanghai Labway Clinical Laboratory Co Ltd (301060) | $130.79 Million | 64.49% | 1.52x | $578.46 Million |
About Shanghai Runda Med Tech Co
Shanghai Runda Medical Technology Co., Ltd. provides medical laboratory services primarily in China. It also engages in the research and development, manufacturing, sale, and service of in vitro diagnostic products, including reagents and other consumables; medical solutions to help healthcare professionals in the areas of diabetes, POCT, clinical chemistry, and immunoassay; professional technica… Read more